Co-Diagnostics (CODX)

Executive Summary

Co-Diagnostics (NASDAQ: CODX) is a molecular diagnostics company leveraging its proprietary CoPrimer™ technology to develop, manufacture, and market infectious disease tests. Its product portfolio includes assays for tuberculosis, hepatitis B/C, HPV, malaria, and SARS-CoV-2. The company operates an FDA-registered and ISO 13485-certified facility in Salt Lake City, Utah, and sells reagents for open-channel PCR systems as well as integrated test kits. With a market capitalization of approximately $8 million, Co-Diagnostics targets clinical, research, and public health markets globally through a distribution network and also licenses its technology via subsidiary CoSara Diagnostics. Despite a competitive landscape, the company's low valuation and focus on underserved diseases like tuberculosis could provide upside if regulatory approvals or commercial traction materialize.

Upcoming Catalysts (preview)

• 2025 Q4FDA clearance or CE marking for expanded tuberculosis test60% success
• 2025 Q3New distribution or licensing deal for CoPrimer technology40% success
• 2025 Q2Positive financial results from COVID-19 test sales recovery30% success